Provided by Tiger Fintech (Singapore) Pte. Ltd.

Processa Pharmaceuticals, Inc.

0.2200
-0.0340-13.39%
Post-market: 0.23190.0119+5.41%19:59 EDT
Volume:1.29M
Turnover:302.09K
Market Cap:1.16M
PE:-0.06
High:0.2599
Open:0.2440
Low:0.1500
Close:0.2540
Loading ...

Processa Pharmaceuticals’ Dr. David Young to Present at World Orphan Drug Congress USA 2025

GlobeNewswire
·
15 Apr

Processa Pharmaceuticals, Inc. (PCSA): Among the Cheapest Stocks Insiders Are Buying Recently

Insider Monkey
·
21 Feb

BRIEF-Processa Pharmaceuticals Inc - On Feb 4, Received Nasdaq Notice For Bid Price Non-Compliance

Reuters
·
11 Feb

Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference

GlobeNewswire
·
07 Feb

Favourable Signals For Processa Pharmaceuticals: Numerous Insiders Acquired Stock

Simply Wall St.
·
07 Feb

Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS
·
31 Jan

BRIEF-Processa Pharmaceuticals Announces Pricing Of $5 Mln Public Offering Priced At-The-Market Under Nasdaq Rules

Reuters
·
28 Jan

Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS
·
28 Jan

Processa Pharmaceuticals Inc - Purchase Price per Share $0.615 for Institutional Investors, $0.7975 for CEO and Board

THOMSON REUTERS
·
28 Jan

Processa Pharmaceuticals Files for Public Offering of up to 9.4 Mln Shares of Common Stock and Accompanying Common Warrants

THOMSON REUTERS
·
16 Jan

Processa Pharmaceuticals files to sell common stock, no amount given

TIPRANKS
·
21 Dec 2024

Processa Pharmaceuticals Price Target Maintained With a $6.00/Share by HC Wainwright & Co.

Dow Jones
·
05 Dec 2024

Processa Pharma Q3 2024 GAAP EPS $(1.03) Misses $(1.00) Estimate

Benzinga
·
31 Oct 2024

Processa Pharmaceuticals Reports Third Quarter Business Highlights and Financial Results

GlobeNewswire
·
31 Oct 2024